AAAAAA

   
Results: 1-10 |
Results: 10
EORTC-10941 - FINAL RESULTS OF A PHASE-II STUDY OF LIAROZOLE FUMARATEIN PATIENTS WITH METASTATIC BREAST-CANCER
Authors: KLIJN J HAMILTON A BEEX L MAURIAC L PARIDAENS R ROY JA AWADA A VANVRECKEM A PALMER P PICCART M
Citation: J. Klijn et al., EORTC-10941 - FINAL RESULTS OF A PHASE-II STUDY OF LIAROZOLE FUMARATEIN PATIENTS WITH METASTATIC BREAST-CANCER, European journal of cancer, 34, 1998, pp. 72-72
EORTC-IDBBC (INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER) - 7 YEARSOF ACTIVE EUROPEAN COLLABORATION
Authors: AWADA A CUFER T BEEX L COLEMAN R PARIDAENS R BRUNING P KLIJN J NOOIJ M MAURIAC L VANVRECKEM A BIGANZOLI L PICCART MJ
Citation: A. Awada et al., EORTC-IDBBC (INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER) - 7 YEARSOF ACTIVE EUROPEAN COLLABORATION, European journal of cancer, 34, 1998, pp. 86-86
MUTATIONS IN THE BRCA1 AND BRCA2 GENES - UPTAKE OF PRESYMPTOMATIC DNATEST, PREVENTIVE CHOICES AND BREAST-CANCER RISK AFTER PROPHYLACTIC MASTECTOMY
Authors: MEIJERSHEIJBOER H VERHOOG L BREKELMANS C VANGEEL B SEYNAEVE C WAGNER A VANDENOUWELAND A FRETS P NIERMEIJER M KLIJN J
Citation: H. Meijersheijboer et al., MUTATIONS IN THE BRCA1 AND BRCA2 GENES - UPTAKE OF PRESYMPTOMATIC DNATEST, PREVENTIVE CHOICES AND BREAST-CANCER RISK AFTER PROPHYLACTIC MASTECTOMY, European journal of cancer, 34, 1998, pp. 95-95
VOROZOLE (RIVIZOR(TM)) - AN ACTIVE AND WELL TOLERATED NEW AROMATASE INHIBITOR FOR THE TREATMENT OF ADVANCED BREAST-CANCER PATIENTS WITH PRIOR TAMOXIFEN EXPOSURE
Authors: PARIDAENS R ROY JA NOOIJ M KLIJN J HOUSTON SJ BEEX LVAM VINHOLES J TOMIAK E VANVRECKEM A LANGENAEKEN C VANGLABBEKE M PICCART MJ
Citation: R. Paridaens et al., VOROZOLE (RIVIZOR(TM)) - AN ACTIVE AND WELL TOLERATED NEW AROMATASE INHIBITOR FOR THE TREATMENT OF ADVANCED BREAST-CANCER PATIENTS WITH PRIOR TAMOXIFEN EXPOSURE, Anti-cancer drugs, 9(1), 1998, pp. 29-35
EORTC-IDBBC (INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER) - 5 YEARSOF EUROPEAN COLLABORATION IN NEW DRUG DEVELOPMENT FOR BREAST-CANCER
Authors: AWADA A VANVRECKEM A PARIDAENS R BRUNING PF KLIJN J TOMIAK E VINHOLES J ROY JA KUSENDA Z BOES GH VANGLABBEKE M PICCART MJ
Citation: A. Awada et al., EORTC-IDBBC (INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER) - 5 YEARSOF EUROPEAN COLLABORATION IN NEW DRUG DEVELOPMENT FOR BREAST-CANCER, European journal of cancer, 33(8), 1997, pp. 1173-1176
TAXOL (T) VERSUS DOXORUBICIN (D) AS FIRST-LINE CHEMOTHERAPY (CT) IN ADVANCED BREAST-CANCER (ABC) - AN EORTC RANDOMIZED STUDY WITH CROSSOVER
Authors: PARIDAENS R BRUNING P KLIJN J GAMUCCI T BIGANZOLI L VANVRECKEM A BOES GH CURRAN D PICCART M
Citation: R. Paridaens et al., TAXOL (T) VERSUS DOXORUBICIN (D) AS FIRST-LINE CHEMOTHERAPY (CT) IN ADVANCED BREAST-CANCER (ABC) - AN EORTC RANDOMIZED STUDY WITH CROSSOVER, European journal of cancer, 33, 1997, pp. 645-645
CORTICOSTEROIDS SIGNIFICANTLY DELAY THE ONSET OF DOCETAXEL-INDUCED FLUID RETENTION - FINAL RESULTS OF A RANDOMIZED STUDY OF THE -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER
Authors: PICCART MJ KLIJN J PARIDAENS R NOOIJ M MAURIAC L COLEMAN R BONTENBAL M AWADA A SELLESLAGS J VANVRECKEM A VANGLABBEKE M
Citation: Mj. Piccart et al., CORTICOSTEROIDS SIGNIFICANTLY DELAY THE ONSET OF DOCETAXEL-INDUCED FLUID RETENTION - FINAL RESULTS OF A RANDOMIZED STUDY OF THE -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER, Journal of clinical oncology, 15(9), 1997, pp. 3149-3155
MULTIDRUG-RESISTANCE PROTEIN IN RECURRENT BREAST-CANCER
Authors: NOOTER K DELARIVIERE GB KLIJN J STOTER G FOEKENS J
Citation: K. Nooter et al., MULTIDRUG-RESISTANCE PROTEIN IN RECURRENT BREAST-CANCER, Lancet, 349(9069), 1997, pp. 1885-1886
AN ONGOING EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCERCROSSOVER TRIAL COMPARING SINGLE-AGENT PACLITAXEL AND DOXORUBICIN AS FIRST-LINE AND SECOND-LINE TREATMENT OF ADVANCED BREAST-CANCER
Authors: PICCARTGEBHART MJ BRUNING P GAMUCCI T KLIJN J ROY JA AWADA A KUSENDA Z VANVRECKEM A PARIDAENS R
Citation: Mj. Piccartgebhart et al., AN ONGOING EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCERCROSSOVER TRIAL COMPARING SINGLE-AGENT PACLITAXEL AND DOXORUBICIN AS FIRST-LINE AND SECOND-LINE TREATMENT OF ADVANCED BREAST-CANCER, Seminars in oncology, 23(5), 1996, pp. 11-15
STEROIDS DO REDUCE THE SEVERITY AND DELAY THE ONSET OF DOCETAXEL (DCT) INDUCED FLUID RETENTION - FINAL RESULTS OF A RANDOMIZED TRIAL OF THEEORTC INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER (IDBBC)
Authors: PICCART MJ KLIJN J PARIDAENS R NOOIJ M MAURIAC L COLEMAN R AWADA A SELLESLAGS J VANVRECKEM A VANGLABBEKE M
Citation: Mj. Piccart et al., STEROIDS DO REDUCE THE SEVERITY AND DELAY THE ONSET OF DOCETAXEL (DCT) INDUCED FLUID RETENTION - FINAL RESULTS OF A RANDOMIZED TRIAL OF THEEORTC INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER (IDBBC), European journal of cancer, 31A, 1995, pp. 347-347
Risultati: 1-10 |